



**Pharmaron Beijing Co., Ltd.**

8th Floor, Block 1

6 Tai-He Road

Beijing Economic Technological Development Zone

Beijing, China

**Pharmaron Beijing Co., Ltd (the “Issuer”)**

**USD 300 Million Zero Coupon Convertible Bonds due 2026**

**(ISIN: XS2352395748) (the “USD Bonds”) and**

**RMB 1,916 Million USD Settled Zero Coupon Convertible Bonds due 2026**

**(ISIN: XS2353011724) (the “RMB Bonds”)**

**(together, the “Bonds”)**

#### **Notice to Bondholders**

*Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the terms and conditions of the Bonds (the “Conditions”).*


The Issuer hereby gives notice that, as approved by the shareholders' meeting dated 31 May 2022 of a final dividend (the “**Final Dividend**”) comprising of (i) a cash dividend of RMB 4.5 (inclusive of tax) per 10 Ordinary Shares and (ii) 5 new Ordinary Shares for every 10 existing Ordinary Shares to be issued out of reserve to all Shareholders, pursuant to Condition 5.3.2(i) and Condition 5.3.3 of the Conditions, the Conversion Prices of each of the Bonds have been adjusted as follows effective 14 June 2022:

- to HKD 166.42 for the USD Bonds (from previously HKD 250.75)
- to HKD 152.32 for the RMB Bonds (from previously HKD 229.50)

**Any Bondholder who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.**

**PHARMARON BEIJING CO., LTD.**

**(康龍化成（北京）新藥技術股份有限公司)**

  
Name: LI Shing Chung Gilbert

Title: Chief Financial Officer

13 June 2022